What Can PMDA do in early development stage of Medical Devices?

Atsushi TAMURA, PhD

International Coordination officer for Medical Devices, Pharmaceuticals and Medical Devices Agency

Agenda

- •PMDA Update
- •PMDA's consultation
- Current Status of Pharmaceutical Affairs
 - Consultation on R&D Strategy

Strengthen Review System in PMDA

Special Assistant for Chief Executive (Feb. 2012)

Office of Review Innovation (Apr. 2012)

Science Board (May 2012)

2 Deputy Directors for Center for Product Evaluation (June 2012)


Organizational Changes(Oct. 2012)


- Office of Cellular and Tissue-based Products (cellular and tissue-based products, CMC of gene therapy products, CMC/quality of biologics, biosimilars, Cartagena Act relatedwork)
- Office of Vaccines and Blood Products (vaccines, blood products, antitoxins)


Strengthen Review System in PMDA

- Enhance partnership with academia -

Set up Office of Review Innovation (April 2012) and the Science Board (May 2012)








Pharmaceutical Affairs Consultation on R&D Strategy


- Background:
 - Universities, Research institutes and venture companies are unfamiliar with the development strategy on the Pharmaceutical Affairs Law
- Purpose:
 - Early approval of innovative drugs and medical devices made in Japan
 - Elimination of drug lag and device lag

Pharmaceutical Affairs Consultation on R&D Strategy

- Major target :
 - Universities, Research institutes and venture companies which have valuable technology and desire medical application
- Summary:
 - Since very early stage, PMDA advises the R&D strategy regarding non-clinical/clinical studies necessary for approval
- Please contact us!!



Flow of R&D Strategy Consultation



10

Thank you!!

http://www.pmda.go.jp/english/



